Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India

Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Butani D, Gupta N, Jyani G, Bahuguna P, Kapoor R, Prinja S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	cost-effectiveness aromatase inhibitor tamoxifen endocrine therapy breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9477f24e1a394e24902920eacd82c44f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9477f24e1a394e24902920eacd82c44f
record_format	dspace
spelling	oai:doaj.org-article:9477f24e1a394e24902920eacd82c44f2021-11-28T19:13:10ZCost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India1179-1314https://doaj.org/article/9477f24e1a394e24902920eacd82c44f2021-11-01T00:00:00Zhttps://www.dovepress.com/cost-effectiveness-of-tamoxifen-aromatase-inhibitor-and-switch-therapy-peer-reviewed-fulltext-article-BCTThttps://doaj.org/toc/1179-1314Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India; 3Department of Radiation Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaCorrespondence: Shankar PrinjaDepartment of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaTel +91 9872871978Email shankarprinja@gmail.comBackground: Breast cancer is the leading cause of cancer among women in India. Treatment with hormone therapy reduces recurrence. We undertook this cost-effectiveness study to ascertain the treatment option offering the best value for money.Methods: The lifetime costs and health outcomes of using tamoxifen, AI and switch therapy were measured in a cohort of 50-year-old women with HR-positive early stage breast cancer. A Markov model of disease was developed using a societal perspective with a lifetime study horizon. Local, contralateral, and distant recurrence were modelled along with treatment related adverse effects. Primary data collected to obtain estimates of out-of-pocket expenditure (OOPE) and utility weights. Both health system cost and OOPE were included. The future costs and consequences were discounted at 3%. A probabilistic sensitivity analysis was used.Results: The lifetime cost of hormone therapy with tamoxifen, AI and switch therapy was to be ₹1,472,037 (I$ 68,947), ₹1,306,794 (I$ 61,208) and ₹1,281,811 (I$ 60,038). The QALYs lived per patient receiving tamoxifen, AI and switch were 13.12, 13.42 and 13.32. tamoxifen was found to be more expensive and less effective. As compared to switch therapy, AI for five years incurred an incremental cost of ₹259,792 (I$12,168) per QALY gained. At the willingness to pay equals to per capita GDP of India, there is 55% probability of AI therapy to be cost-effective compared to switch therapy.Conclusion: In postmenopausal women with HR-positive early-stage breast cancer, switch therapy is recommended for use on the basis of cost-effectiveness.Keywords: cost-effectiveness, aromatase inhibitor, tamoxifen, endocrine therapy, breast cancerButani DGupta NJyani GBahuguna PKapoor RPrinja SDove Medical Pressarticlecost-effectivenessaromatase inhibitortamoxifenendocrine therapybreast cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 625-640 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cost-effectiveness aromatase inhibitor tamoxifen endocrine therapy breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cost-effectiveness aromatase inhibitor tamoxifen endocrine therapy breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Butani D Gupta N Jyani G Bahuguna P Kapoor R Prinja S Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
description	Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India; 3Department of Radiation Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaCorrespondence: Shankar PrinjaDepartment of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaTel +91 9872871978Email shankarprinja@gmail.comBackground: Breast cancer is the leading cause of cancer among women in India. Treatment with hormone therapy reduces recurrence. We undertook this cost-effectiveness study to ascertain the treatment option offering the best value for money.Methods: The lifetime costs and health outcomes of using tamoxifen, AI and switch therapy were measured in a cohort of 50-year-old women with HR-positive early stage breast cancer. A Markov model of disease was developed using a societal perspective with a lifetime study horizon. Local, contralateral, and distant recurrence were modelled along with treatment related adverse effects. Primary data collected to obtain estimates of out-of-pocket expenditure (OOPE) and utility weights. Both health system cost and OOPE were included. The future costs and consequences were discounted at 3%. A probabilistic sensitivity analysis was used.Results: The lifetime cost of hormone therapy with tamoxifen, AI and switch therapy was to be ₹1,472,037 (I$ 68,947), ₹1,306,794 (I$ 61,208) and ₹1,281,811 (I$ 60,038). The QALYs lived per patient receiving tamoxifen, AI and switch were 13.12, 13.42 and 13.32. tamoxifen was found to be more expensive and less effective. As compared to switch therapy, AI for five years incurred an incremental cost of ₹259,792 (I$12,168) per QALY gained. At the willingness to pay equals to per capita GDP of India, there is 55% probability of AI therapy to be cost-effective compared to switch therapy.Conclusion: In postmenopausal women with HR-positive early-stage breast cancer, switch therapy is recommended for use on the basis of cost-effectiveness.Keywords: cost-effectiveness, aromatase inhibitor, tamoxifen, endocrine therapy, breast cancer
format	article
author	Butani D Gupta N Jyani G Bahuguna P Kapoor R Prinja S
author_facet	Butani D Gupta N Jyani G Bahuguna P Kapoor R Prinja S
author_sort	Butani D
title	Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
title_short	Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
title_full	Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
title_fullStr	Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
title_full_unstemmed	Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
title_sort	cost-effectiveness of tamoxifen, aromatase inhibitor, and switch therapy (adjuvant endocrine therapy) for breast cancer in hormone receptor positive postmenopausal women in india
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/9477f24e1a394e24902920eacd82c44f
work_keys_str_mv	AT butanid costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia AT guptan costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia AT jyanig costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia AT bahugunap costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia AT kapoorr costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia AT prinjas costeffectivenessoftamoxifenaromataseinhibitorandswitchtherapyadjuvantendocrinetherapyforbreastcancerinhormonereceptorpositivepostmenopausalwomeninindia
_version_	1718407783956611072

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India

Ejemplares similares